Daptomycin therapy failure in an adolescent with methicillin-resistant Staphylococcus aureus bacteremia. Pediatr Infect Dis J 2009 May;28(5):445-7
Date
03/20/2009Pubmed ID
19295462DOI
10.1097/INF.0b013e3181927891Scopus ID
2-s2.0-67649531477 (requires institutional sign-in at Scopus site) 16 CitationsAbstract
Daptomycin is a Food and Drug Administration-approved alternative to vancomycin for the treatment of serious methicillin-resistant Staphylococcus aureus infections in adults. Treatment failure with daptomycin is increasingly reported in adults, but data in children are limited. We report an adolescent patient with severe burn injuries who had persistent methicillin-resistant Staphylococcus aureus bacteremia and rapidly developed nonsusceptibility to daptomycin. We review the relevant literature.
Author List
Jacobson LM, Milstone AM, Zenilman J, Carroll KC, Arav-Boger RAuthor
Ravit Boger MD Chief, Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAnti-Bacterial Agents
Bacteremia
Daptomycin
Drug Therapy, Combination
Gentamicins
Humans
Male
Methicillin-Resistant Staphylococcus aureus
Microbial Sensitivity Tests
Staphylococcal Infections
Vancomycin